Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chlorpheniramine + phenylephrine (Centaur Pharmaceuticals)
- Development stage
- Unknown
- Lead developer
- Centaur Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Sinarest AF New is a fixed-dose combination of chlorpheniramine and phenylephrine developed by Centaur Pharmaceuticals. It is primarily indicated for the symptomatic relief of the common cold, allergic rhinitis, and upper respiratory tract allergies in pediatric patients. Chlorpheniramine is a first-generation antihistamine that acts as an inverse agonist at the histamine H1 receptor, effectively reducing symptoms such as sneezing, runny nose, and watery eyes. Phenylephrine is a sympathomimetic decongestant that selectively stimulates alpha-1 adrenergic receptors on vascular smooth muscle, causing vasoconstriction in the nasal mucosa to alleviate nasal congestion and sinus pressure.
- Brand names
- Sinarest AF NewSinarest AF New DropsSinarest AF New SyrupSinarest AF New Tablet
- Other names
- chlorpheniramine + phenylephrine hydrochloridechlorpheniramine maleate + phenylephrinechlorpheniramine maleate + phenylephrine hydrochloride
02
Targets
ADRA1A (α1A)HRH1 (Histamine H1 Receptor)ADRA1B (α1B)ADRA1D (α1D)
Beyond the preview
Go deeper on chlorpheniramine + phenylephrine (Centaur Pharmaceuticals).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chlorpheniramine + phenylephrine (Centaur Pharmaceuticals).